Role of tristetraprolin phosphorylation in paediatric patients with inflammatory bowel disease

Alessia Di Silvestre1, Marianna Lucafò2, Letizia Pugnetti1

  • 1PhD School in Science of Reproduction and Development, University of Trieste, Trieste 34127, Italy.

Insights

Phosphorylated Tristetraprolin (TTP) binds to 14-3-3 protein, promoting inflammation in pediatric inflammatory bowel disease (IBD). This study found increased phospho-TTP/14-3-3 complex in IBD tissues and macrophages, correlating with higher TNF-α levels.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) involves intestinal inflammation and epithelial injury, driven by excessive pro-inflammatory cytokine expression.
  • Tristetraprolin (TTP) regulates inflammatory factors by binding cytokine mRNAs; its phosphorylation state dictates its mRNA-degrading activity.
  • Phosphorylated TTP (phospho-TTP) forms a complex with 14-3-3, potentially exacerbating intestinal inflammation.

Purpose of the Study:

  • To investigate the role of TTP phosphorylation in pediatric IBD.
  • To determine if the phospho-TTP/14-3-3 complex is associated with IBD pathogenesis in children.

Main Methods:

  • Analysis of inflamed and non-inflamed colonic mucosa from pediatric IBD patients.
  • Experiments on macrophages differentiated from IBD patients' blood, with healthy donors as controls.
  • Co-immunoprecipitation and immunoblotting to detect phospho-TTP/14-3-3 complex formation.
  • Evaluation of TNF-α expression as a key pro-inflammatory marker.

Main Results:

  • Elevated expression of TTP and the phospho-TTP/14-3-3 complex was observed in inflamed IBD colonic mucosa compared to non-inflamed samples.
  • IBD-derived macrophages showed significantly higher levels of TTP and the phospho-TTP/14-3-3 complex than those from healthy controls.
  • Increased TNF-α expression was detected in both inflamed IBD tissues and IBD-derived macrophages.

Conclusions:

  • This study establishes a novel association between the phospho-TTP/14-3-3 complex and pediatric IBD.
  • Higher levels of the phospho-TTP/14-3-3 complex in IBD samples suggest its contribution to disease progression.
  • The findings highlight the potential of targeting the TTP/14-3-3 interaction in IBD treatment.
Abstract

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
417
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
416
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
432
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
589
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
382
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
411